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Translational relevance:  129 (120-150 words) 
Identifying diagnostic, prognostic, and theragnostic factors is key in the modern 
management of cancer patients, including myeloma. Here we designed a next-
generation sequencing targeted capture over 125 myeloma specific genes and the 
canonical translocation loci in order to identify the mutations, copy number, and 
translocation makeup of newly diagnosed myeloma patients and use this to identify 
independent features associated with outcome. Using this approach, we were able to 
identify different markers as well as their interaction with one another and both confirm 
previous findings and identify new changes associated with outcome. The originality of 
this dataset resides in the extensiveness of features analyzed and the long-term follow 
up of this trial population. Therefore, the novel markers identified will help add precision 
to the management of newly diagnosed myeloma patients treated in an intensive 
setting.   
Abstract (250) 
Purpose: Copy number changes and translocations have been studied extensively in 
many datasets with long term follow-up. The impact of mutations remains debated given 




Methods: we performed targeted panel sequencing covering 125 myeloma-specific 
genes and the loci involved in translocations in 223 newly diagnosed myeloma samples 
recruited into one of the Total Therapy Trials (TT).  
Results: As expected, the most commonly mutated genes were NRAS, KRAS, and 
BRAF making up 44% of patients. Double-Hit, BRAF and DIS3 mutations had an impact 
on outcome alongside classical risk factors in the context of an intensive treatment 
approach. We were able to identify both V600E and non-V600E BRAF mutations, 58% 
of which were predicted to be hypoactive or kinase dead. Interestingly, 44% of the 
hypoactive/kinase dead BRAF mutated patients showed co-occurring alterations in 
KRAS, NRAS or activating BRAF mutations suggesting they play a role in the 
oncogenesis of multiple myeloma (MM) by facilitating MAPK activation and may lead to 
chemo resistance.  
Conclusion: Overall, these data highlight the importance of mutational screening to 
better understand newly diagnosed MM (NDMM) and may lead to patient specific 






Multiple Myeloma (MM) is a hematological malignancy of plasma cells that afflicts 
around 30,000 people in the US per year with a five-year survival rate of 47%.1 High risk 
MM (HRMM) is seen in up to 30% of newly diagnosed cases whose outcome, in 
contrast to the majority of MM cases, has seen very little improvement over the past 15 
years2 with a median progression free survival (PFS) of 1.8 years and overall survival 
(OS) of 2.6 years.3 There is, therefore, a clear need to identify these patients in order to 
apply relevant new approaches in their management.  
The study of MM has identified many genetic events that are associated with event free 
survival (EFS) and overall survival (OS). Some of these features occur with a greater 
frequency in HRMM cases, including translocations into the immunoglobulin (Ig) loci 
involving chromosomes 4 and 16, which define two etiological subgroups [t(4;14), 15%, 
and t(14;16), 5%].4 Other instability mechanisms associated with HRMM include 
additional structural variations such as del(1p), and del(17p), jumping translocations of 
1q and secondary translocations to MYC at 8q24.5–7  
A great deal is known about the genetics of MM with over 800 genomes and 2000 
exomes sequenced.4,6,8–13 However, the prognostic impact of mutations has not been 
widely evaluated and available datasets have generally had a relatively short follow-up 
ranging from 22 to 25 months, with one dataset being up to 5.4 years.4,11 These 
analyses have identified a diverse range of mutations that are associated with outcome, 





Despite falling prices, it is not feasible to run whole exome sequencing (WES) for every 
MM patient, and even then, many translocations outside of the capture region would be 
missed, requiring a combination of fluorescence in situ hybridization (FISH) or gene 
expression profiling. Since this approach is time and cost prohibitive it has led to the 
adoption of targeted sequencing to generate data in a timely, cost-effective manner. 
This led us to design a custom myeloma targeted panel, which provided rapid, fiscally 
responsible characterization of patient subgroups.  
We evaluated this panel on 223 newly diagnosed MM (NDMM) patients included in the 
Total Therapy (TT) trials and correlated results to both gene expression and clinical 
data, with the ultimate aim of this work being to effectively characterize NDMM patients 
and identify the impact of mutations long-term.  
Methods  
Patients and Samples 
A total of 223 previously untreated NDMM patients recruited to the TT trials between 
February 2004 and August 2017 were included after written informed consent. The 
sample collection protocol was approved by the UAMS Institutional Review 
Board (protocol #2012-12). The TT trials are a series of phase II and III, alkylator heavy, 
double transplant-based clinical trials for first line myeloma treatment that all include 
both proteasome inhibitors and immunomodulatory drugs (IMiDs). A summary of the 
treatments received may be found in Supplemental Figure 1. Eighty-five of these 




processing may be found in the Supplemental Methods. This study was performed in 
accordance to the 1964 Helsinki Declaration. 
 
Sequencing  
Panel design: Genes and chromosomal regions relevant to the biology, prognosis and 
treatment of MM were identified. This information was used to design and implement a 
targeted panel to identify common and important genomic abnormalities in MM. Probes 
capture exonic regions for the relevant genes (n~125) including +/- 10 base pairs (bp), 
to include splice site variants, Supplemental Table 1. Single nucleotide polymorphisms 
(SNPs) with a minor allele frequency >0.35 were captured in regions of interest to infer 
copy number using allelic imbalance combined with read depth ratio. In this way both 
deletions and gains were confidently assayed. SNPs in GC-rich regions were avoided to 
prevent hybridization artefacts and low depth problems. To identify Ig translocations the 
V, D and J segments along with entire constant region were tiled (81.8-90.2 Mb, 17.4-
32.6 Mb,106.0-107.3 Mb for IGK, IGL, and IGH respectively.4,14,15 MYC translocations 
were also detected by tiling 2 Mb upstream and downstream of MYC (126.3-130.8 Mb).  
Targeted sequencing: The panel was divided into a translocation panel and a 
mutation/copy number panel to provide high depth coverage for mutation analysis (0.6 
Mb), whilst providing lower depth sequencing of translocation regions (4.2 Mb). 
Each patient had their tumor DNA from bone marrow and control DNA from peripheral 
blood sequenced, to identify somatic mutations, copy number changes and 




(Kapa Biosystems) and split for hybridizing to both mutation and translocation captures 
(SeqCap EZ target enrichment; Nimblegen), after which mutation and translocation 
captures were combined. The HiSeq 2500 or NextSeq500 (Illumina, San Diego, CA, 
USA) were used for sequencing with 75 bp paired-end reads. The median value of the 
mean coverage of each sample was 135x and 452x for translocations and mutations, 
respectively. 
Data analysis  
bcl2fastq was used for demultiplexing and BWA mem (v. 0.7.12) for alignment to 
Ensembl (GRCh37/hg19) human reference genome. Strelka (v.1.0.14) was used for 
variant calling and single nucleotide variants (SNVs) were filtered using fpfilter 
(https://github.com/ckandoth/variant-filter). Indels were filtered using a 10% variant 
allele frequency (VAF) cut-off. Variants were annotated using Variant Effect Predictor 
(v.85).  To determine copy number, a normalized depth comparison between tumor and 
control samples was used and segments of SNP variance were utilized to identify 
regions of chromosomal deletion and gain. Copy number was manually normalized 
based on the ratio and SNP allele calls using the best fitting chromosomes with the 
least variance (usually chromosome 2 or 10). Data were visualized using a custom built 
R-Shiny application. Intra- and inter-chromosomal rearrangements were called using 
Manta (v0.29.6) with default settings and the exome flag specified. QC metrics 
estimated the cross-sample contamination of samples using homozygous SNPs in the 
germline with 95% or higher VAF examined in the tumor sample. A VAF density plot on 
those SNPs was generated, as well as reporting the minimum, maximum and median of 




Validation and comparison datasets 
SNVs: SNVs were compared and validated using seven samples (Horizon Diagnostics) 
with known SNVs and VAF. The VAF of mutations found in the validation samples 
matched those found on the panel with r2=0.93, Supplemental Figure 3. 
FISH: Copy number data generated from the sequencing panel were validated against 
existing FISH data for del(1p) (1p13 FISH vs. 1p12 (FAM46C) seq.), gain (3 copies) 
/amp (4 copies or more) (1q21), del(13q) (D13S31 vs. RB1), and del(17p) (TP53). Plots 
of comparisons between FISH and sequencing data are shown with specificities and 
sensitivities of each region at the 20%, 25%, 40%, and 50% FISH cut-off, 
Supplemental Figure 4 and Supplemental Table 2. An additional comparison for 
TP53 was made using the prognostic cut-off 55%.16 All deletions identified by FISH 
were identified using the targeted panel. Five additional deletions were called using the 
panel, 3/5 of them having a del(17p) in at least 20% of cells by FISH, Supplemental 
Figure 5 and 20. 
Comparison dataset. Gene mutations were compared to the MGP dataset (n=1273)3 
available in the European Genomic Archive under accession numbers 
EGAS00001001147, EGAS00001000036 and EGAS00001002859, or at dbGAP under 
accession number phs000748.v5.p4. 
Gene expression profiling  
Total RNA from plasma cells was used for gene expression profiling (GEP) using U133 




Affymetrix Microarray GCOS1.1 software. GEP70, TC classification and molecular 
clusters were derived as previously published.17  
BRAF mutation analysis 
The predicted functions of BRAF mutations were determined using the Clinical 
Knowledgebase (CKB) database18 using the mutations present in the MGP dataset 
(n=103)8 and this dataset (n=26).  
Data Availability 
Sequencing data and expression data have been deposited in the European Genomic 
Archive under the accession numbers EGAS00001003223 and EGAD00001004117.  
Statistical analysis and additional methods may be found in Supplemental methods.  
Results  
Patients characteristics 
A total of 223 patients were sequenced and included in the study. Overall, they were 
representative of a fit-newly diagnosed population. The median follow-up time from 
diagnosis was 8.14 years (95% CI 7.39-9.02). The median OS was not met at the time 
of analysis and the 8-year OS was 61% (95% CI 54-69%). The median EFS was 6.16 
years (95% CI 5.18-7.75). A summary of patient characteristics may be found in Table 
1.  
The incidence of translocation and copy number were in keeping with previously 
published data. MYC translocations were identified in 26% of cases: they involved the Ig 




within the previously published hotspots Supplementary Figure 6A. MYC deletions 
and gain were seen in 16% and 28% of patients, respectively. An example may be seen 
in Supplementary Figure 7. Overall, MYC events were seen in 47% of patients. A 
summary of the translocations and comparison to the MGP3 data may be found in 
Supplemental Table 11. 
The most commonly mutated genes were KRAS (23% of patients), NRAS (17% of 
patients) and BRAF (12% of patients), Figure 1A, in keeping with previously published 
datasets. The incidence of mutations was similar to the MGP study, Supplemental 
Table 4.  
Exome sequencing identifies an APOBEC-derived mutational signature in 
approximately 80% of t(14;16) samples.19 We performed nNMF analysis on our targeted 
sequencing in order to determine if we can identify an APOBEC signature, which was 
seen in seven patients (3.2%), five of which had a t(14;16) and one a t(14;20) 
translocation, Figure 1C and Supplemental Figure 8. Both frequency and enrichment 
for the MAF subgroups were in keeping with previous reports.19  
 
Interactions between genomic abnormalities and Double-Hit myeloma  
Pearson’s correlation identified a significant correlation between CYLD mutations and 
deletions (r=0.31, p=2.07x10-7), TRAF3 mutations and deletions (r=0.34, p=1.5x10-7), 
and TP53 mutations and deletions (r=0.32, p=1.12x10-6), as previously reported.4,8 ATM 
mutations were positively correlated with the t(14;16) subgroup (r=0.40, p=3.33 x10-7) 




significant negative correlation between DIS3 mutations and hyperdiploidy (HRD) (r=-
0.11, p=0.09) in this dataset although they were positively correlated to the presence of 
t(4;14) (r=0.21, p=0.0005). On the other hand, del(13q) was negatively correlated to 
HRD (r=-0.26, p=0.0001), Figure 1B.  
We identified 8.1% patients with Double-Hit (ISS III plus amp(1q) or biallelic inactivation 
of TP53) which is not significantly different to the 6.1% of patients previously described. 
Double-Hit was associated with both an adverse EFS (median: 24.6 months (95% CI 
10.6-42.7) versus and 6.77 years ((95% CI 5.60- ∞), p<0.0001) and OS 37.3 months 
((95% CI 32.3-∞) versus 64% at 8 years ((95% CI 57%-73%), p<0.0001). Interestingly, 
when analyzing the impact of Double-Hit in the TT population, which received two 
autologous stem cell transplants (ASCTs), the impact of Double-Hit was still significant. 
This is of particular interest in a double-ASCT population, Supplemental Figure 9, 
identifying a population who still has a dire outcome despite intensive treatment.  
 
Survival analysis identifies that BRAF and DIS3 mutations are associated with an 
adverse outcome with long-term follow-up.  
Univariate analysis 
Power estimation was performed, Supplemental Figure 10. The results of univariate 
analyses for EFS and OS for molecular features are shown, Figure 2. Overall, this 
dataset behaved as expected with del(12p), del(17p), gain/amp(1q), and del(1p) being 
significantly associated with both adverse EFS and OS. Trisomy(9) and trisomy(19) 




better EFS. The other trisomies (3, 15 and 21) had no impact on outcome. Sixteen 
percent of patients were considered as high risk according to the GEP70 score and they 
had a worse outcome than standard risk patients both in terms of EFS (HR=2.5 ((95% 
CI 1.6-3.9), p<0.0001) and OS (HR=3.5 ((95% CI 2.1-6), p<0.0001), Supplemental 
Figure 11. The PR subgroup, was also associated with both short EFS and OS 
whereas the MF and MS subgroup were associated with a short EFS. Based on their 
ISS, 26.5%, 43.5% and 30% of patients were considered ISS I, ISS II and ISS III 
respectively with a HR of death of 2.7 ((95% CI 1.2-5.9), p=0.01) and 6.04 ((95% CI 2.8-
13) p<0.0001) for ISS II and III respectively in comparison to ISS I. MYC translocations, 
gains and deletions, were associated with a difference in OS in this dataset, but not 
EFS Supplemental Figure 6. In terms of mutations, BRAF mutations were associated 
with an adverse EFS (HR=2 (95% CI 1.2-3.3), p=0.009) and OS (HR=2.7 (95% CI 1.5-
4.7), p=0.0007), Supplemental Figure 16 A-B. TP53 and DIS3 mutations were 
associated with a worse EFS (HR=2.3 (95% CI 1.3-4.2), p=0.0065 and HR=2 (95% CI 
1.2-3.5), p=0.009 respectively) but not OS (HR=1.5 (95% CI 0.67-3.2), p=0.34 and 
HR=1.2 (95% CI 0.56-2.4), p=0.68) respectively). We went on to test combinations of 
markers previously published such as DNA repair pathway mutations4 and bi-allelic 
TP533. As previously shown4, DNA repair pathway mutations defined by the presence of 
an ATM or ATR mutation were associated with an adverse outcome in terms of EFS 
(HR=2.1 (95% CI 1.1-4.1), p=0.023) and OS (HR=2.2 (95% CI 1.1-4.6, p=0.033)), as 
was bi-allelic TP53 (HR=4.3 (95% CI 2.4-7.7), p<0.0001) and OS (HR=2.8 (95% CI 1.4-
5.6), p=0.004). There was no significant impact of IGL translocations on outcome, 





Multivariate Analysis Identifies Mutations of BRAF and DIS3 As Independently 
Associated With Prognosis 
We went on to perform a multivariate analysis using all the genetic features with p<0.1.  
For EFS, a protective effect was associated with trisomy(19). An adverse association 
was seen for Double Hit, del(1p)(FAF1), t(4;14), del(12p)(KDM5A) and mutations of 
BRAF and DIS3 (Corrected C-index=0.689). Similarly, for OS, trisomy(19)  was 
associated with a positive effect, whereas an adverse association was seen with Double 
Hit, del(1p)(FAF1), del(12p)(KDM5A), gain8q24 (MYC) and mutations of BRAF 
(Corrected C-index=0.73). With the long follow-up there was consistency between 
markers in the multivariate analysis of EFS and OS, with the exception of MYC gains 
and mutation of DIS3, indicating a high reliability in the dataset. A summary of the 
multivariate may be found in Figure 3 and Supplemental Table 6-7. 
We tested the solidity of this analysis by repeating the analysis using classical risk 
factors and previously published models such as the IFM2009 model20 and GEP7017, 
Supplementary Figure 13-15. DIS3 mutations and BRAF mutations retained their 
prognostic significance, irrespective of other high-risk features.  
DIS3 mutations and biallelic DIS3 events are associated with poor prognosis in 
MM 
In our dataset we identified 21 patients (9.4%) with a DIS3 mutation. The majority of the 
mutations were missense and were located throughout the gene suggesting they were 




DIS3 were associated with a worse EFS (HR=2 (1.2-3.4), p=0.01) but not OS. A similar 
trend was seen in the Myeloma XI dataset and the MGP, Supplemental Figure 17. 
Biallelic events were seen in 11 (5%) patients, mostly consisting of deletions and 
mutations (91%, n=10/11). There was no case of biallelic deletion. Bialleleic DIS3 
events had a stronger association with EFS (HR for progression of 3.6 (1.8-7.2), 
p<0.0001) than monoallelic events (HR of 1.2 (0.85-1.8), p=0.27), Figure 4 B-C.  
BRAF non-V600E mutations comprise kinase dead variants which were 
associated with adverse outcome, and may lead to increase MAPK activation 
through CRAF via co-occurring KRAS and NRAS mutations 
BRAF mutations were associated with an adverse outcome in this cohort, 
Supplementary Figure 16 A-B. Forty-six percent (n=12/26) were at the classical 
V600E hotspot, Figure 5A. When comparing the impact of the non-V600E versus the 
V600E patients, for EFS especially, most of the prognostic impact appeared to driven by 
non-V600E mutations, (1.3 years (0.58-∞) versus 5.6 years (2.46-∞), p=0.02 for EFS; 
3.12 years (1.21-∞) versus 8.62 years (5.73-∞), p=0.08 for OS), Supplementary Figure 
16 C-F.  
From a functional perspective, BRAF mutations can be sub-divided into activating or 
non-activating, based on information from other cancers. Using the CKB database, we 
were able to dissect the non-V600E mutations into activating (n=5), inactivating (n=8), 
and unknown (n=1) Supplementary Table 8. The outcome of patients with the 
inactivating mutations was worse (HR=6.4 (2.74-15), p<0.0001) than those who had an 
activating mutation (HR=2.1 (1.05-4.2), p=0.04), which in turn was worse than those 




MGP dataset subset of patients who received an autologous stem cell transplant (OS, 
p=0.008), Supplemental Figure 17. 
To explore this further, we expanded this analysis (n=26) using the MGP dataset 
(n=103). Combined, forty-three percent (56/129) were V600E mutations, 11% (14/129) 
were predicted to be activating, 8.5% with hypoactive (11/129), 25% kinase dead 
(32/129) and 12.5% unknown (16/129).  
In melanoma inactivating mutations often co-occur with other MAPK alterations such as 
NRAS or KRAS mutations, NF1 biallelic inactivation or PTPN11 mutations, and 
contribute to increased MAPK signaling through enhanced binding and recruitment of 
CRAF.21 We hypothesized that the adverse outcome associated with inactivating BRAF 
mutations in myeloma is due to increased MAPK signaling, in which case co-occurring 
NRAS or KRAS mutations would need to be present in the same clone.  
NRAS, KRAS, and BRAF mutations are believed to be mutually exclusive4,8 in MM. In 
most cases, these three mutations were also mutually exclusive (Supplemental Figure 
18 A-B), however, inactivating BRAF mutants co-occurred more frequently with NRAS, 
KRAS, or activating BRAF mutations than expected, reaching 44% of patients with 
inactivating BRAF mutations (p=0.0018), Figure 5E. To determine if the co-occurring 
mutations were present in the same clone we calculated the cancer clonal fraction 
(CCF) of the mutations and, based on the resulting proportions, assessed whether they 
were in the same clone. We identified that of the 68% (n=13/19) of samples with an 
inactivating BRAF mutation had a co-occurring NRAS/KRAS mutation in the same clone 
and 32% (n=6/19) could not be determined from the data, Figure 5F and 






The incorporation of the complete spectrum of genomic lesions from translocation to 
mutations including copy number changes is required to gain insight and accurately 
predict outcome in MM. Using multiple techniques to determine these factors is both 
labor intensive, time consuming, and yields high failure rates given the amount of tumor 
cells required.22 Next-generation sequencing has helped unravel the genetic complexity 
of MM but cost and time are often setbacks in a clinical setting. Many targeted 
approaches have been developed, some specific to MM23,24 and some applicable to 
MM,25 but most do not take into account the Ig loci, thus requiring combinations with 
other tests such as FISH or GEP to identify translocations. Like Bolli et al,24 our 
approach offers a complete view of translocations, CNA, and mutations. The set of 
genes in this capture largely overlaps the Sanger capture but given our wide MYC tiling 
we offer a better understanding of the complex rearrangements that occur on 8q24. 
Finally, given the size of this capture, we are also able to identify an APOBEC 
signature, that has also demonstrated prognostic significance in MM.19 
Here we show that an increased follow-up of patient outcome data combined with 
targeted sequencing can identify consistent genomic markers associated with inferior 
outcome. We identified the classical cytogenetic abnormalities, such as t(4;14), del(1p) 
and del(12p), as affecting outcome, as well as the more recently defined Double-Hit 
myeloma.  In addition, we identify that mutations in BRAF and DIS3 are prognostically 




In the MGP dataset we have previously shown that Double-Hit myeloma resulted in a 
worse outcome for PFS and OS, irrespective of the treatment used, but these patients 
mostly had a single autologous stem cell transplant (ASCT). ASCT is the standard of 
care for all NDMM aged ≤65 and before the era of novel agents ASCT proved beneficial 
on OS.26  Double transplants were subsequently investigated and deemed safe,27–51 
and two randomized trials confirmed the benefit of double versus single transplant in 
terms of OS.26  In this dataset, all patients received a double ASCT, but despite this 
Double-Hit patients still perform badly, although they have a slightly better outcome than 
was seen in the MGP data (20.7 months (95% CI 17.4-20.6)), with a 16-month 
improvement in their outcome.  
BRAF mutations were seen in 11% of myeloma patients and were associated with a 
poor outcome. BRAF is mutated in numerous cancers and the substitution of a valine 
(V) for a glutamic acid (E) residue at position 600 in the kinase domain is the most 
common BRAF mutation.31 This mutation mimics the phosphorylation of the activation 
loop, thereby inducing constitutive BRAF kinase activation. BRAFV600E mutations are 
present in 50% of melanoma patients and 2% of non-small cell lung cancer (NSCLC) 
patients. In NSCLC, they are associated with a shorter OS and resistance to cisplatinum 
chemotherapy.32 The clinical significance of BRAFV600E in multiple myeloma has been 
characterized in two previous studies where seven myeloma patients with BRAFV600E 
had significantly shorter OS and an increased incidence of extra medullary disease 
(57% vs. 17%) compared with wild-type BRAF.33 More recently Rustad et al.34 reported 
a good response to broad acting drugs and no relation to prognosis among eleven 




Fifty-four percent of the BRAF mutations seen in this dataset were non-V600E and is a 
similar rate to that seen in NSCLC35,36 and other MM datasets.37 The biology of these 
non-V600E mutants is heterogeneous, with some leading to high kinase activity (class I 
and II) and Ras independence while others are hypoactive or kinase dead (class III) 
variants but nonetheless these still impact on the MAPK pathway through CRAF 
heterodimerization.38,39 In our dataset the hypoinactive/kinase dead variants were more 
likely to co-occur with a KRAS or NRAS mutation which has also has been previously 
described by Lionetti et al.37 In melanoma, biallelic NF1 inactivation or PTPN11 
activation have also been linked to MAPK activation through inactive BRAF mutants,37,40 
but these are rare events in MM and they were not associated with non-BRAFV600E 
mutants, Supplemental Figure 19.  
BRAFV600E mutations in melanoma are sensitive to the BRAF inhibitors vemurafenib and 
dabrafenib. Case reports41,42 and clinical trials43 also support the use of vemurafenib in 
this setting. These drugs are not effective against non-BRAFV600E mutations, but could 
be targeted using MEK inhibitors.  
In other cancers, the presence of concomitant NRAS/KRAS and BRAF kinase dead 
mutations results in chemoresistance.35,44 Identifying these non-BRAFV600E mutants 
would not only help identify patients who should not receive BRAF inhibitors but also 
patients who would not benefit from intensive alkylator heavy regimens. The adverse 
outcome of these patients in this dataset could suggest that heavily treating these 
patients may be deleterious and may suggest they would benefit from alkylator free 




The prognostic impact of chromosome 13 has been long debated. Forty percent of 
patients have a del(13q) either by a monosomy 13 (35%) or a simple loss of 13q.45 
Del(13q) was found to be associated with a short outcome in many studies, before the 
associations between t(4;14) and del(13q) were made.46 DIS3 is located on 
chromosome 13 and as such is frequently deleted, as well as being mutated in MM.4,8 
More recently, DIS3 germline variants have been described in familial cases of plasma 
cell disorders.47 Combined, we saw DIS3 events in 53% of cases and bi-allelic events in 
5%. We identified an association with poor outcome and bi-allelically affected DIS3, 
which may suggest that DIS3 is a tumor suppressor gene.  However, the majority of 
DIS3 mutations are missense and not nonsense or frameshift mutations, further the 
mutations are clustered at particular codons which is not typical of a tumor suppressor 
gene and may suggest an oncogenic potential for DIS3. In this respect, the mutations 
may cause a change of function, as has recently been suggested in yeast where point 
mutations are associated with genome instability.48 Given the role of DIS3 in RNA 
processing49 it is possible that complete inactivation of both alleles is lethal, as has been 
seen for SF3B1.48  
BRAF and DIS3 mutations have an impact on outcome alongside classical risk markers 
in the context of the TT trials. We were able to identify both BRAFV600E mutations and 
non-V600E BRAF mutations, 58% of which were predicted to be hypoactive or kinase 
dead. Interestingly, 44% of the hypoactive/kinase dead BRAF patients showed co-
occurring mutations in KRAS or NRAS, suggesting they play a role in the oncogenesis 




These data highlight the importance of mutational screening to better understand 
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Figure legends  
Figure 1: General features of the cohort. A. The proportion of patients with each 
mutation. B. Correlation plot representing the different significant interactions. C. 
Dendrogram of the nNMF identifying an APOBEC signature among the 223 TT baseline 
samples using the targeted panel.   
Figure 2: Summary of the univariate analysis. A. EFS. B. OS. Forest plots 
representing the result of the univariate analysis. In red, those that were significantly 
associated with outcome at the level of p<0.05, in blue the non-significant variables.  
Figure 3: Multivariate analysis. Forest plots representing the results of the multivariate 
analysis for A. EFS and B. OS. 
Figure 4: DIS3 mutations. A. Distribution of DIS3 mutations throughout the gene. B. 
DIS3 mutations are associated with an adverse EFS. C. Biallelic DIS3 inactivation is 
associated with a worse outcome than monoallelic inactivation.   
Figure 5: Inactivating BRAF mutations affect outcome and co-occur with NRAS or 
KRAS mutations. A. Stick plot representing the locations of the different BRAF 
mutations in the MGP dataset (above) and this dataset (below). Differential impact of 
BRAF mutations depending on predicted function on EFS (B) and OS (C). D. The 
spectrum of BRAF mutations with co-occurring mutations. E. The proportion of cases 
with co-occurring MAPK (NRAS/KRAS/activating BRAF mutations) depending on their 








Table 1: Summary of patient’s characteristics and comparability to the complete 
TT trial population. 
 
 
 223-baseline study Combined TT3a-3b-4-
4like-5a-5b-6 
Number of patients 223 1039 
Inclusion dates 02/2004 to 08/2017 02/2004 to 08/2017 
Median Follow Up 8.14 years 
(95% CI 7.39-9.02) 
8.35 years 
(95% CI 8.00-8.63) 
Median EFS 6.16 years 
(95% CI 5.18-7.75) 
4.8 years 
(95% CI 52%-58%) 
8- year OS 61% (95% CI 54-69%) 42% (95% CI 39%-45%) 
Median age (years) 59 (range: 30-75) 61 (range: 30-76) 
Sex ratio M:F 1.8:1 1.6:1 
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